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Abstract
In molecular epidemiological studies of drug resistant Mycobacterium tuberculosis (TB) in Sweden a large outbreak of an
isoniazid resistant strain was identified, involving 115 patients, mainly from the Horn of Africa. During the outbreak period,
the genomic pattern of the outbreak strain has stayed virtually unchanged with regard to drug resistance, IS6110 restriction
fragment length polymorphism and spoligotyping patterns. Here we present the complete genome sequence analyses of
the index isolate and two isolates sampled nine years after the index case as well as experimental data on the virulence of
this outbreak strain. Even though the strain has been present in the community for nine years and passaged between
patients at least five times in-between the isolates, we only found four single nucleotide polymorphisms in one of the later
isolates and a small (4 amino acids) deletion in the other compared to the index isolate. In contrast to many other
evolutionarily successful outbreak lineages (e.g. the Beijing lineage) this outbreak strain appears to be genetically very
stable yet evolutionarily successful in a low endemic country such as Sweden. These findings further illustrate that the rate
of genomic variation in TB can be highly strain dependent, something that can have important implications for
epidemiological studies as well as development of resistance.
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Introduction
Tuberculosis (TB) is a major global health concern and the
increasing drug resistance makes TB-control even more demand-
ing. Without adequate chemotherapy transmission of drug
resistant TB will continue, and the suffering of the individual
patients will increase. Concomitantly with the introduction of
modern TB drugs over half a century ago, morbidity and mortality
was dramatically reduced in countries like Sweden. Yet, TB
remains a global epidemic, with one-third of the world’s
population infected, at least 9.9 million new active cases and 1.8
million deaths in 2008 [1]. In a recent survey, drug- and multidrug
resistance (MDR, i.e. resistance to at least rifampicin (RIF) and
isoniazid (INH)) was assessed, and the median global prevalence of
drug resistance was estimated to be 20% [2]. The distribution of
resistance varies substantially world wide with resistance to at least
one drug ranging from 0% in some small Western European
countries to 56.3% in Azerbaijan, and MDR TB ranging from 0%
to 22.3%, again with highest frequency in Azerbaijan. An
estimated 2.9% of all new TB cases worldwide have MDR-TB.
Strains resistant also to the agents used in the therapy of MDR-TB
such as the fluoroquinolone ofloxacin (OFL) and the injectable
second-line drugs amikacin (AMI) were more recently described
and named extensively drug resistant (XDR) [3]. A growing
proportion of such XDR-TB cases will seriously obstruct TB
control globally [4,5].
In molecular epidemiological studies of drug resistant TB in
Sweden a large outbreak of INH resistant TB was identified,
mainly involving patients originating from the Horn of Africa.
One exceptionally large cluster, SMI-049, was identified during
the study period [6]. Beginning in 1996, two patients belonging to
this cluster were identified per year, until 1999 when suddenly 19
new patients were identified. The identification of isolates
belonging to cluster SMI-049 during several years and the large
accumulation of new cases in 1999 indicated an active spread of
TB in Sweden. For this reason a more thorough investigation was
initiated in 2000 by the Swedish National Board of Health and
Welfare. Yet, in spite of awareness of the outbreak, and
strengthened contact investigations, new cases continued to appear
(Fig. 1), first at a decreasing pace, then in 2005 again rapidly
increasing. Up to date (November 2010) 115 patients infected with
the cluster SMI-049 strain have been identified. Twenty-two
patients belonging to cluster SMI-049 were Swedish born, and
appeared in the later phase of the outbreak, indicating that the
epidemic had gradually taken hold in the Swedish born
population. Despite the extensive spread of this particular M.
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unchanged since its discovery with regard to drug resistance,
IS6110 restriction fragment length polymorphism (RFLP)- and
spoligotyping patterns. The apparent genetic stability together
with the extensive spread of this strain in a low endemic country
like Sweden led us to further characterize if the strain possess any
particular genetic factors that could explain its evolutionary
success and genetic stability.
Here we present a detailed analysis of the M. tuberculosis strain
causing the cluster SMI-049 outbreak. The genomes of the isolate
of the index case, and two SMI-049 isolates with isolation dates
differing from the index strain by 9 years, were sequenced by
massive parallel DNA sequencing using the 454-platform.
Comparisons were made with previously sequenced M. tuberculosis
strains and regions of known importance to antibiotic resistance
and virulence were studied more closely. Phylogenetic studies and
studies of M. tuberculosis sequence variation have previously mainly
focused on unrelated isolates and not looked at whole genome
sequences of clinically traceable strains over prolonged time.
Interestingly, although the three isolates were obtained with 9
years in-between the only differences found on the whole genome
scale were four single nucleotide polymorphisms (SNP) in one of
the later isolated strains and a four amino-acids in-frame deletion
in the second strain compared to the index strain. This shows that
the cluster SMI-049 strain is exceptionally stable genetically and
yet evolutionarily very successful and that clonally disseminated M.
tuberculosis strains can stay virtually unchanged over many years
and multiple transmission cycles.
Methods
Bacterial isolates
During the years 1994–2010, drug resistant (DR) Mycobacterium
tuberculosis isolates were obtained from all the six Swedish TB
laboratories in Gothenburg, Linko ¨ping, Malmo ¨/Lund, Stockholm
and Umea ˚. In Sweden, all isolates are tested for susceptibility to
the first-line drugs isoniazid (INH), ethambutol (EMB) and
rifampicin (RIF). During the major part of the study all isolates
were also tested for susceptibility to streptomycin (SM), except for
the years 2004–2010, when the Linko ¨ping and Stockholm
laboratories stopped testing for SM-resistance, since SM no longer
was used for treatment of TB patients in Sweden. All laboratories
had taken part in the external quality assurance program for drug
susceptibility testing of M. tuberculosis offered by the Swedish TB
reference laboratory at the Swedish Institute for Infectious Disease
Control (SMI), Solna, Sweden. The first isolate from each patient
was included in the study.
RFLP
The isolates were cultured on Lo ¨wenstein-Jensen medium.
DNA was extracted by resuspending two blue loops of bacteria in
450 mL TE buffer pH 8.0 (10 mM Tris-HCl, 1 mM EDTA) and
then heated at 80uC for 20 min. The cells were further freeze
thawed twice and 30 mL of lysozyme (20 mg/mL) was added and
incubated for 2 h at 37uC. Seventy mL of 10% sodium dodecyl
sulfate (SDS) and 5 mL of proteinase K (10 mg/mL) were added to
the lysate, vortexed and incubated for 10 min at 65uC followed by
addition of 100 mL of 5 mol/L NaCl and 100 mL of 10% N-cetyl-
N,N,N-trimethyl ammonium bromide. The tubes were vortexed
until the solution was white and incubated for 10 min at 65uC.
DNA was extracted by two chloroform-isoamyl alcohol (24:1, vol/
vol) treatments, precipitated by addition of cold isopropanol and
the pellet was redissolved in TE buffer. RFLP typing was
performed using the insertion sequence IS6110 as probe and
PvuII as restriction enzyme [7,8]. Visual bands were analyzed
using the BioNumerics software version 6.01 (Applied Maths,
Kortrijk, Belgium). Strains with identical RFLP patterns (100%
similarity) and consisting of five bands or more were judged to
belong to a cluster. On the basis of the molecular sizes of the
hybridizing fragments and the number of IS6110 copies of each
isolate, fingerprint patterns were compared by the un-weighted
pair-group method of arithmetic averaging using the Jaccard
coefficient. Dendrograms were constructed to show the degree of
relatedness among strains according to a previously described
algorithm [9] and similarity matrixes were generated to visualize
the relatedness between the banding pattern of all isolates.
Spoligotyping
All isolates were also characterized by spoligotyping [10]. The
patterns obtained by spoligotyping were compared by visual
examination and by sorting the results in BioNumerics. Spoligo-
types in binary format were entered in the SITVIT2 database
(Pasteur Institute of Guadeloupe), which is an updated version of
the previously released SpolDB4 database [11], and were assigned
to the major phylogenetic lineages according to signatures
provided in SITVIT2, which defines 62 genetic lineages/
sublineages of M. tuberculosis complex strains. At the time of the
present study, SITVIT2 contained global genotyping information
Figure 1. Number of new cases in cluster SMI-049 identified per year. The number of new cases belonging to the SMI-049 cluster is
displayed for each year. Gray portions of bars represent foreign born patients, black portions of bars represent Swedish born patients.
doi:10.1371/journal.pone.0016647.g001
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countries of origin, with more than 3000 spoligo-international-
types (SITs).
Three isolates, one from the index case, and two isolated nine
years after the index case, were subjected to further analysis as
follows:
Drug susceptibility testing
Drug susceptibility testing for the drugs SM, EMB, RIF, AMI
and OFL was performed at SMI by the radiometric BACTEC 460
assay according to the instructions of the manufacturer (Becton
Dickinson Biosciences, Sparks, MD). The results were in
accordance with those previously obtained at the regional
laboratory.
Sanger sequencing
Sanger DNA sequencing of the 980-bp fragment of inhA promoter
region was performed using primers previously described [12],
sequencing of the cluster SMI-049 specific variations in the polA,
PPE55 and cyp138 genes was performed using the following primers:
polA_Fwd 59-CTGCAACTGGTCAGTGACGA, polA_Rev 59-
CGCAACACCCGAAACTCCA, PPE55_Fwd 59-GTTGACATT-
GCCAGGGTTGA, PPE55_Fwd2 59-GGATGTCGAACAGCGA-
CATG, PPE55_Rev 59- CAATGTCGGGTTCGGCAACT, PPE-
55_Rev2 59-AACCTGGGCAACCACGTGTC, PPE55_Rev3 59-
ACCTGAATCCGCTGAACATC, CYP138_Fwd 59-ATGGCGA-
TCCCGACGTCTTC, CYP138_Rev 59-CCAGCCTTTCACCC-
GAACTC. All Sanger sequencing was performed using The BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems).
Whole genome sequencing
Massive parallel sequencing using the 454-technology (Roche)
was performed at the sequencing facility at the SMI. Chromo-
somal DNA of the S96-129, BTB05-552 and BTB05-559 isolates
was extracted as for the RFLP analysis except for two additional
extractions with chloroform-isoamylalcohol (24:1, vol/vol). DNA
was sequenced using the 454-FLX technology using the manu-
facturer’s instructions (www.454.com) and data were processed
with the accompanying software package. This generated 464949
and 502523 reads giving mean genome coverage of 23 and 24
times for S96-129 and BTB05-552, respectively. Isolate BTB05-
559 was sequenced both using 454-FLX technology and also using
the 454-Titanium upgrade generating a combined number of
373176 reads and a 32 times mean coverage. Gapped genome
sequences of the three isolates have been deposited at GenBank as
whole genome shotgun projects under accession numbers
AEGB00000000 (S96-129), AEGC00000000 (BTB05-552) and
AEGD00000000 (BTB05-559). The versions described in this
paper are the first versions, xxxx01000000.
Bioinformatics
Assembly and analysis of 454-sequencing data were performed
with the CLC Genomics Workbench v3.7 (CLC Bio, Aarhus,
Denmark). Assemblies were performed for each isolate individu-
ally and also as a combined assembly including all sequence data
for a deeper coverage of the common features of the cluster SMI-
049 isolates. Large sequence polymorphisms (LSP) between cluster
SMI-049 isolates and H37Rv (NC_000962) were identified by
detecting assembly positions with partially matching reads and the
source of variation elucidated by a combination of de novo assembly
of non-assembled reads, reference assembly of the SMI-049 data
on the other three fully sequenced M. tuberculosis genomes H37Ra
(NC_009525), CDC1551 (NC_002755) and F11 (NC_009565)
and manual sequence identification of partially matching reads.
SNP analysis was performed for each sequenced isolate after the
large sequence polymorphisms had been introduced into a
modified H37Rv-SMI049 reference genome to avoid false calls
related to assembly problems at locations of large rearrangements.
Analysis parameters were as follows: average base quality filter
cutoff 15, central base quality filter cutoff 20, minimum variation
frequency cutoff 75%, maximum variation (ploidy) 2, minimum
sequence coverage 3. The SNP results for the three sequenced
genomes were compared and all SNP calls that were not found in
all three or had a variation frequency ,90% were manually
verified in the assemblies. Absence of sequence coverage at the
position of an SNP in one or two of the sequences is denoted in
Table S3.
Growth rate and TNF induction in macrophages
Peripheral blood mononuclear cells (PBMCs) were isolated from
the buffy coats of blood samples from healthy donors by density
gradient centrifugation (Lymphoprep, Axis-Shield, Oslo, Norway).
Monocytes were separated from PBMCs using CD14-positive
magnetic beads (Miltenyi, Bergisch Gladbach, Germany) and were
more than 98% pure. Monocytes were cultured in DMEM
supplemented with 10% FCS, 1 mM sodium pyruvate, 50 U/ml
penicillin, 50 mg/ml streptomycin (all from Gibco, Paisley, UK)
and 40 ng/ml rhM-CSF (Peprotech, Rocky Hill, NJ, USA). On
day 2 in culture, culture medium was exchanged, antibiotics
withdrawn, and the cells were cultured for another three days to
differentiate into macrophages.
Macrophages were seeded in 24-well plates (Nunc, Roskilde,
Denmark) at a density of 5610
5/well or in Lab-Tek chamber
slides (Nunc, Roskilde, Denmark) at a density of 3610
5/well. After
24 h cells were infected with mycobacteria at a multiplicity of
infection of 1:1. Three different mycobacterial strains were used:
H37Rv (ATCC 27294), and the two cluster SMI-049 isolates S96-
129 (isolate from index case) and BTB05-552 (late isolate). After
3 h, the cells were extensively washed to remove extracellular
bacteria and were cultured for 6 days in DMEM.
On day 0, 1, 3 and 6 infected macrophages were lysed with
0.05% Triton X-100, lysates were plated on 7H11 Middlebrook
agar and colony-forming units (cfu) were enumerated after 3–4
weeks. Macrophages in chamber slides were fixed with 4%
paraformaldehyde and intracellular acid-fast bacteria were
visualized using Kinyoun stain. Cells containing different numbers
of bacteria were counted under 1000-fold magnification in
consecutive microscope fields until a total of at least 10
3 cells
was attained and expressed as proportion of total number of
infected cells.
TNF was quantified in culture supernatants harvested at
different time points, using an ELISA according to the
manufacturer’s protocol (BD OptEIA Sets, BD Biosciences, San
Diego, CA, USA).
Results
Cluster SMI-049
During the years 1996-2010 115 cluster SMI-049 isolates from
the same number of patients were isolated and characterized by
drug susceptibility testing, IS6110 RFLP, and spoligotyping. The
cluster is defined by a low-level resistance to INH, a 14-band
IS6110 RFLP pattern and a spoligotyping pattern belonging to
SIT52, of the T2 lineage, according to the SITVIT2 database
(Fig. 2). Three isolates from three different patients were selected
for further characterization. The first isolate (S96-129) from
August 1996 was from the source case, a 19-year old male
TB Outbreak Strain SMI-049 Genomes
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The second isolate (BTB05-552) from September 2005 was from a
28-year old Swedish woman and the third isolate (BTB05-559)
from August 2005 was from a 6-year old Swedish born girl. In a
timetable of cluster occurrence based on the estimated time for the
development of first symptoms consistent with TB, isolate S96-129
is believed to be the source of the cluster (number 1), while
BTB05-559 is number 88 and BTB05-552 is number 95 [13].
The cluster SMI-049 strain had been circulating in the
population for about nine years between the time of diagnosis of
the source case and the two other cases. In a chain of transmission
the isolate BTB05-552 had been transmitted through at least three
patients, more probably four patients, excluding the source case
and case number 95 from which it was isolated, and the isolate
BTB05-559 had been transmitted from the source case through
two or three patients before infecting case number 88.
Whole genome sequencing
Massive parallel sequencing of the genomes of M. tuberculosis
isolates S96-129, BTB05-552 and BTB05-559 was performed
using the Roche 454-sequencing technology. The mean sequence
coverage of the genomes were 23, 24 and 32 times respectively and
the completeness of the genome sequences were estimated to be
98% for all isolates. Zero coverage regions that could not be
ascribed to deletions compared to the H37Rv reference genome
were all located at loci with higher than average GC content,
mainly in PE-PGRS genes (Polymorphic GC Rich Sequences),
that are known to be difficult to sequence due to their high GC
content [14,15].
Differences between isolates of cluster SMI-049
The three sequenced isolates had identical IS6110 RFLP- and
spoligotyping patterns like all 115 cluster SMI-049 isolates (Fig. 2).
This pattern was very stable, in only one case a strain isolated from
a patient belonging to the cluster in 2000 demonstrated a RFLP
pattern with one extra band indicative of a new IS6110 insertion
event. The sequenced genomes each contain 18 copies of IS6110
but the theoretical RFLP pattern fits well with the obtained 14-
band pattern since some fragments have very similar sizes and will
migrate together thus resulting in a lower than expected number of
visible bands on the gel. However, the PvuII site in gene Rv2017
(with an IS6110 inserted downstream) appears to be partially
resistant to cleavage and only results in a weak band at 1735 bp.
Instead, cleavage at the next following PvuII site results in a clear
band at 2728 bp.
Comparison of the generated genome sequences reveals that the
three sequenced isolates do not differ by any large sequence
polymorphisms (LSPs). The only differences found were four SNPs
in BTB05-559 and a four amino acids in-frame deletion in
BTB05-552 compared to the index isolate S96-129. All differences
were verified by manual Sanger sequencing. The SNPs in BTB05-
559 consist of a synonymous C -.T transition at nucleotide
position 579 in the polA gene (encoding DNA polymerase I) and
three SNPs in the PPE55 gene that all result in amino acid changes
(N1496Y, T1517A, I1520V). PPE55 belongs to a group of highly
variable M. tuberculosis specific proteins with unknown function but
that are highly immunogenic and secreted by the Type VII
secretion pathway [16,17]. The in-frame deletion in BTB05-552
removes amino acids 404-407 (out of 441) of the putative
cytochrome P450 protein Cyp138.
Comparison of cluster SMI-049 with H37Rv and other M.
tuberculosis genomes
A total of 65 LSPs were identified between the SMI-049 isolates
and H37Rv (33 insertions, 26 deletions, 6 combined insertion/
deletions) with sizes of 9–6831 bp (Table S1). Twenty-five of these
were associated with differences in the presence of the mobile
insertion element IS6110. The second most common group of
changes was copy number differences in regions of short intergenic
repeats. The net difference in DNA content in the SMI-049
isolates is an addition of 9103 bp compared to H37Rv. In total, 33
of the polymorphisms were intergenic while 32 affected annotated
genes. Twenty-four LSPs were unique to the SMI-049 cluster (i.e
not found in any other M. tuberculosis genome at NCBI) and 12 of
these affected annotated genes, 5 deletions and 7 IS6110 insertions
(Table 1). Of the five deletions, three affected PE or PPE-genes
(PE-PGRS44, PPE38, PPE39, PPE57-59). Five large regions not
present in H37Rv (1674 bp, 6836 bp, 953 bp, 5000 bp and
6771 bp in length, respectively (Table S1)) results in a total of 15
extra genes that are present in the SMI-049 strains but absent
from H37Rv. However, all these regions are present in the
CDC1551 strain and represent regions deleted in H37Rv. None of
them have been reported to be important for virulence.
SNP and small deletion/insertion polymorphism (DIP), 1–6 bp
length, analyses were performed after the large sequence
polymorphisms had been introduced into a modified H37Rv-
SMI049 reference genome to avoid false calls related to assembly
problems at locations of large rearrangements. The SNP and small
DIP results were compared to the resequencing results of H37Rv
[15,18] and 90 SNPs and 11 DIPs resulting from identified errors
in the H37Rv sequence were removed. In total, the cluster SMI-
049 sequences differ from H37Rv by 777 SNPs (781 in BTB05-
559, see above) and 44 small DIPs (Tables S2 and S3). Of the
SNPs 73 occurred in intergenic regions and 724 in annotated
genes. The majority of SNPs (56%) were non-synonymous in
concordance with previous reports [18,19,20] illustrating the low
level of purifying selection in M. tuberculosis. Premature stop-codons
were found in six genes (Table 2). Of these only bglS (beta-
glucosidase) and lpdA (lipoamide dehydrogenase) encode proteins
with known functions and the premature stop codons occur at the
very end of both genes.
Figure 2. Stability in IS6110 RFLP and spoligotyping patterns. IS6110 RFLP and spoligotyping patterns of the three SMI-049 isolates S96-129,
BTB 05-552 and BTB 05-559. Approximate molecular weights are indicated in kilo base pairs next to the RFLP gel picture. Spoligotype products 1–43
are depicted as black (positive) and white (negative) boxes.
doi:10.1371/journal.pone.0016647.g002
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049 and 16 of these resulted in frame shifts in annotated genes, five
of which have predicted functions, nanT, fadD35, ltp1, lppH and
gidB (Table 3). The first four are involved in lipid biosynthesis and
transport and it is not clear what effect knock out of these genes
may have on cell viability. However, GidB has recently been
shown to be a highly conserved 7-methylguanosine (m
7G)
methyltransferase responsible for methylation of position G527
of the 16S rRNA [21]. All three strains sequenced have a deletion
of G102 of the gidB gene. Loss of function of GidB is associated
Table 1. SMI-049 specific large polymorphisms.
Reference position
(H37Rv)
Allele
variations
Size
(bp) Overlapping annotations Change
164574-164585 Deletion 12 Gene: Rv0136 cyp138. 4 amino acids deletion specific for BTB05-552. No frameshift
888927-889020 Deletion 94 Intergenic: Deletion of 94 bp compared to H37Rv
1533690 Insertion 1413 Intergenic: IS6110 insertion not present in H37Rv
1541951 Variation 44 Intergenic: IS6110 insertion site 44 bp downstream of corresponding IS6110 in H37Rv
1987503 Insertion 1362 Gene: Rv1755 39 part of plcD: Insertion of IS6110 199 bp upstream and in reversed orientation
compared to H37Rv
Disruption
1987697-1989024 Inversion 1299 IS6110 in reversed orientation compared to H37Rv
2038790-2039673 Insertion/
deletion
1355/883 Gene: Rv1798 lppT, Putative lipoprotein: Truncated by IS6110 insertion and deletion of 883 bp Disruption
2163462 Insertion 1497 Gene: Rv1917c PPE34: Insertion of IS6110 and 135 bp not present in H37Rv Disruption
2245301 Insertion 1358 Gene: Rv2000, hypothetical protein: Insertion of IS6110 not present in H37Rv Disruption
2367679 Insertion 1359 Intergenic: Insertion of IS6110 not present in H37Rv
2634069-2635575 Deletion 1507 Genes: Rv2352c and Rv2353c, PPE38 and PPE39: Deletion of 1507 bp compared to H37Rv.
Smaller than DS9 [66]
Frameshift
2636931 Insertion 156 Intergenic: Insertion of 156 bp compared to H37Rv
2902567-2904318 Insertion/
deletion
122/1752 Genes: Rv2578c and Rv2579 dhaA, hypothetical protein and haloalkane dehalogenase:
Deletion of 1752 bp + insertion of 122 bp
Disruption
2937529-2937530 Deletion 9 Gene: Rv2591 PE-PGRS44: Deletion of 9 bp compared to H37Rv No frameshift
3125851 Insertion 1358 Gene: Rv2818c, hypothetical protein: Insertion of IS6110 not present in H37Rv Disruption
3192248 Insertion 53 Intergenic: Insertion of 53 bp compared to H37Rv, intergenic repeat region
3378898 Insertion 1359 Gene: Rv3019c, esxR secreted ESAT-6 like protein: Insertion of IS6110 not present in H37Rv Disruption
3550843 Insertion 1357 Gene: Rv3183, possible transcriptional regulatory protein: Insertion of IS6110 not present in
H37Rv
Disruption
3594319-3594430 Deletion 112 Intergenic: Deletion of 112 bp compared to H37Rv, intergenic repeat region
3710316-3711736 Insertion/
deletion
6771/1421 Genes: Rv3325 and Rv3326, IS6110 transposases: IS6110 replaced by 6771 bp insertion
flanked by two IS6110 in reversed direction, similar to CDC1551
Deletion
3803868-3803918 Deletion 51 Intergenic: Deletion of 51 bp compared to H37Rv
3842289-3847214 Deletion 4926 Genes: Deletion of Rv3425 to Rv3428c, PPE57 and PPE59 joined and IS1532 element lost
through deletion of 4926 bp probably through homologous recombination via large repeat region.
Similar to DS13 [66]
Deletion
4172770 Insertion 1358 Intergenic: IS6110 insertion not present in H37Rv
4348818 Insertion 59 Intergenic: Insertion of 59 bp compared to H37Rv, intergenic repeat region
doi:10.1371/journal.pone.0016647.t001
Table 2. SMI-049 specific SNPs resulting in premature stop codons.
Reference position
(H37Rv) Reference Allele variations Overlapping annotations Amino acid change
218204 C T Gene: Rv0186 bglS, beta-glucosidase R646 Stp (691 aa)
281238 C T Gene: Rv0235c, probable transmembrane protein W459 Stp (482 aa)
2129419 G T Gene: Rv1879, hypothetical protein E15 Stp (378 aa)
2374245 C T Gene: Rv2114, hypothetical protein Q138 Stp (207 aa)
3689523 G T Gene: Rv3303 lpdA, Lipoamide dehydrogenase C472 Stp (493aa)
4351039 G T Gene: Rv3872 PE35 E99 Stp (99aa)
doi:10.1371/journal.pone.0016647.t002
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genes affected by DIPs either encoded hypothetical proteins
(N=4) or belong to PPE or PE-PGRS gene families (N=6).
Positional effects of IS6110 insertions
M. tuberculosis contains several mobile insertion sequences (IS)
[23]. IS6110 is a member of the IS3-family and is found in almost
all members of the M. tuberculosis complex in varying number of
copies. Integration of IS6110 can, depending on the site of
insertion, result in phenotypic changes in the host bacterium, both
detrimental as well as occasionally beneficial (Reviewed in [24]).
To determine if any obvious effects of IS6110 insertions could be
predicted, we analyzed the insertions of IS6110 in the SMI-049
cluster genomes in more detail. Eight IS6110 insertions occur in
annotated genes in SMI-049 and the affected open reading frames
are most likely completely disrupted (Table 1). As expected, none
of the affected genes are reported to be essential for M. tuberculosis.
Notably, the PPE34 and plcD genes are the genes with most
detected individual IS6110 insertions in clinical isolates of M.
tuberculosis [25] and disruption of these genes have been speculated
to result in changes in the immunological interaction with the host
[26,27,28,29]. Of the remaining genes with insertions of IS6110,
two have predicted functions, one in lipid biosynthesis (lppT) and
one as a secreted ESAT-6-like gene (esxR) and four are
hypothetical genes. Over-representation of IS6110 insertion in
hypothetical genes has been noted earlier [25].
Apart from disrupting genes, IS6110 insertions have also been
found to activate gene expression of nearby genes by an outward
directed promoter (OP6110) at the 39 end of the insertion element
[30,31,32]. To assess if any IS6110 insertions in the SMI-049
genomes could account for differences in virulence by the OP6110
promoter we mapped what genes were present nearby inserted
IS6110 (Table 4). Apart from the truncated genes that harbored
an IS6110, and most likely are non-functional, five genes were
found at a reasonable distance from an IS6110 and oriented in the
forward direction compared to OP6110, an IS1547 transposase,
PPE36, PE27A, moaC (molybdenum cofactor biosynthesis protein
C) and an oxidoreductase with unknown specificity. Of these
genes, changed expression of PPE36 and PE27A might result in
changes in the immunogenic response.
Growth rate and TNF induction in human macrophages
Cluster SMI-049 isolates S96-129 and BTB05-552 grew in
macrophages as indicated by a successive increase in cfu in
macrophage lysates (Fig. 3A) and an increase of proportion of cells
containing higher numbers of bacteria over time (Fig. 3B). The
growth rate of both SMI-049 cluster isolates was similar and
comparable to that of the H37Rv laboratory strain until day 3. Of
note, at day 6 less bacteria were recovered from cluster SMI-049-
infected macrophages as compared with day 3, while macrophages
infected with H37Rv showed further increment in cfu at that time
point (Fig. 3A). Microscopic analysis of chamber slide cultures
revealed that there was augmented death of macrophages infected
with the SMI-049 isolates on day 6 as indicated by increased
number of cells with fragmented cytoplasm and pycnotic nuclei;
no increased cell death was observed in H37Rv-infected
macrophages (not shown). Interestingly, from the day 4 post-
infection SMI-049-infected macrophages produced much greater
amounts of TNF than macrophages infected with H37Rv (Fig. 3C).
Drug resistance genes
When tested by the BACTEC 460 reference method all three
isolates were resistant to isoniazide (INH) at 0.2 mg/L. S96-129
was resistant to streptomycin (SM) at 4 mg/L whereas BTB05-552
Table 3. SMI-049 specific small deletion and insertion polymorphisms (DIP).
Reference position
(H37Rv) Reference Allele variations Overlapping annotations Change
33203 G - Intergenic
336684 A - Gene: Rv0279c PE_PGRS4 Frameshift
336694 - C Gene: Rv0279c PE_PGRS4 Frameshift
671259 -- TG Gene: Rv0577 TB27.3, hypothetical protein Frameshift
789689 G - Intergenic
839545 - G Gene: Rv0747 PE_PGRS10 Frameshift
1178876 AT -- Intergenic
1242287 G - Gene: Rv1118c, hypothetical protein Frameshift
1280683 ------ CGAAGT Gene: Rv1153c omt, Putative O-methyltransferase No frameshift
1537711 AC -- Intergenic
1982962 C - Gene: Rv1753c PPE24 Frameshift
2046760 C - Gene: Rv1803c PE_PGRS32 Frameshift
2149855 - A Gene: Rv1902c nanT, sialic acid-transport integral membrane protein Frameshift
2821079 GG -- Gene: Rv2505c fadD35, Putative acyl-CoA synthetase Frameshift
3006362 G - Gene: Rv2689c, hypothetical protein Frameshift
3100153 - A Gene: Rv2790c ltp1, Putative lipid -transfer protein Frameshift
3742352 C - Gene: Rv3345c PE_PGRS50 Frameshift
4018414 - A Gene: Rv3576 lppH, Putative lipoprotein Frameshift
4117362 C - Gene: Rv3677c, Putative hydrolase Frameshift
4408101 C - Gene: Rv3919c gidB, 7-methylguanosine (m
7G) methyltransferase Frameshift
doi:10.1371/journal.pone.0016647.t003
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three isolates were susceptible to the first line drugs rifampicin
(RIF), ethambutol (EMB) and pyrazinamide (PZA). These isolates
were also susceptible to the second line drugs ofloxacin (OFL) (at
2 mg/L) and amikacin (AMI) (1 mg/L). Genes previously
reported to be involved in resistance to antibiotics used to treat
M. tuberculosis infections (rpoB – RIF; katG, inhA, oxyR-ahpC, iniBAC
and furA – INH; rrs, rpsL and gidB – SM; pncA – PZA; embB – EMB;
gyrA and gyrB –OFL) were specifically monitored for non-
synonymous mutations that may change the tolerance to these
antibiotics. Low-level INH resistance of cluster SMI-049 strains is
explained by a -15 C to T transition in the promoter region of the
inhA gene, which encodes an enoyl acyl carrier protein reductase
involved in fatty acid synthesis [33]. This mutation has been
reported as the second most common resistance mutation to INH
and is most often associated with low (,10 ug/ml) level resistance
[34,35,36,37,38]. Twenty-five randomly chosen isolates belonging
to the SMI-049 cluster were also found to contain this mutation
(data not shown). Only one other change was found in a gene
previously reported to be involved in INH resistance, iniA Q394E,
a substitution that has never been reported to alter drug
susceptibility.
As noted above, all three isolates contain a deletion of G102 in
the gidB gene that previously has been reported to result in low-
level SM resistance [21,22]. The low-level of resistance reported
earlier for gidB mutants is just at the clinical break point and this
may explain why S96-129 was found to be resistant while BTB05-
552 and BTB05-559 were susceptible. No changes were found in
rrs or rpsL genes that could explain the differences in SM
susceptibility between the isolates.
The gyrA gene of all three isolates contain five non-synonymous
mutations (E21Q, T80A, A90G, S95T and G668D) compared to
H37Rv. Interestingly, change of alanine at position 90 to valine is
commonly reported in quinolone resistant isolates [39,40,41] but
change to a glycine in combination with the T80A mutation has
instead been reported to result in hypersensitivity to quinolones
[42]. This finding led us to determine the MIC for OFL more
precisely by testing all three isolates at 2, 1, 0.5 and 0.25 mg/L.
No growth was detected at any of these concentrations (only
without antibiotics) and the MIC for OFL is therefore ,=0.125,
well below the average wild-type distribution MIC of 0.5 [43].
This is interesting since the T80A mutation is a marker for the
Uganda genotype [44]. The S95T mutation is known as a
naturally occurring polymorphism among quinolone susceptible
strains [45,46] and E21Q and G668D are attributed to H37Rv
specific differences and present in many other susceptible strains
and should therefore not contribute any resistance.
Phylogenetic background of SMI-049
Phylogenetically the SMI-049 isolates were of the modern
principal genetic group 2 (PGG2) defined by katG463 and gyrA95
SNPs (katG463 CGG (Arg) and gyrA95 ACC (Thr)) [45]. By
extended SNP analysis (Filliol 2006) they were found to belong to
SNP cluster group 5 (SCG-5), which is predominant in Uganda
[47]. The RFLP pattern of the cluster SMI-049 strain matches
(92%) with a strain (BEA000007341) from Rwanda recorded in
the international database of IS6110 RFLP patterns maintained at
RIVM, Bilthoven, the Netherlands, also indicating that the strain
may have its origin in sub-Saharan Africa. According to the
Table 4. Putative genes where IS6110 insertions may alter promoter activity.
Position of
OP6110 in
SMI-049
Downstream
gene Function Distance
Orientation of
downstream
gene Comment
890769-890838 Rv0797 IS1547 Transposase 94 bp Forward
1537121-1537190 Rv1362c Hyp. Prot., unknown function 398 bp Reversed
1545719-1545788c Rv1368 lprF, probable lipoprotein 272 bp Reversed
1992219-1992288 Rv1755c plcD 59, Phospholipase C - truncated 86 bp Reversed IS6110 inserted into plcD
2000585-2000654 Rv1758 cut1 39, Serine esterase, hydrolysis
of cutin - truncated
66 bp Forward IS6110 inserted in cut1, Non-
functional [79]
2051273-2051342 Rv1799 lppt 39, probable lipoprotein - truncated 82 bp Forward IS6110 inserted into lppT
2175810-2175879c Rv1917c PPE34 39, unknown function - truncated 81 bp Forward IS6110 inserted into PPE34
2260061-2260130 Rv2000 Hyp. Prot. 39, unknown function - truncated 85 bp Forward IS6110 inserted into Rv2000
2280108-2280177 Rv2117 Transcriptional regulator protein 155 bp Reversed
2387585-2387654 Rv2108 PPE36, unknown function 119 bp Forward
2652563-2652632 Rv2356c PPE40, unknown function 994 bp Reversed
3132243-3132312 Rv2813 Hyp. Prot., unknown function 1495 bp Reversed
3137724-3137793 Rv2818c Hyp. Prot. 39, unknown function - truncated 82 bp Forward IS6110 inserted into Rv2818c
3392133-3392202c Rv3019c esxR 59, secreted ESAT-6 like protein - truncated 82 bp Reversed IS6110 inserted into esxR
Rv3018A PE27A, unknown function 564 bp Forward
3565496-3565565 Rv3182 Hyp. Prot., unknown function 210 bp Reversed
3723555-3723624c Rv3324A Pseudogen 84 bp Forward IS6110 inserted into Rv3324A
Rv3324c moaC, molybdenum cofactor biosynthesis protein C 194 bp Forward
3728662-3728732c MT3429 Hyp. Prot., unknown function 79 bp Reversed Identical to MT3429 of CDC1551,
not present in H37Rv
4184858-4184927 Rv3727 Oxidoreductase 269 bp Forward
doi:10.1371/journal.pone.0016647.t004
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placed the SMI-049 strain in the Lineage 4 (red) Europe and
Americas lineages, with 2/3 matches to the ‘‘Uganda’’ cluster
within the PGG2 group.
By spoligotyping all cluster SMI-049 isolates were of the T2
lineage, which is geographically linked to East Africa [11]. All
isolates had the spoligotype international type SIT52. The
sequenced isolates also lacked the region of difference 724
(RD724), a polymorphism that defines one major sub-lineage of
M. tuberculosis commonly seen in the central African human host
population, and which is common in isolates from Uganda
[48,49]. Together with a T2 specific spoligotype pattern [18]
RD724 defines the ‘‘Ugandan genotype’’ [48], again supporting
the concept that the cluster SMI-049 strain has its origin in
Central/Eastern Africa.
Discussion
The SMI-049 outbreak is one of the largest outbreaks of TB
ever reported from low endemic countries. A few other outbreaks
Figure 3. Virulence of SMI-049 isolates in human macrophages. Monocyte-derived human macrophages were infected with strain H37Rv or
SMI-049 isolates S96-129 or BTB05-552, at multiplicity of infection 1:1. Intracellular bacterial growth was determined by enumeration of cfu in plated
macrophage lysates (A) or by estimation of proportion of cells containing varying amounts of bacteria (B) over time. TNF induction in infected
macrophages was quantified by ELISA using culture supernatants harvested at different time points post-infection (C).
doi:10.1371/journal.pone.0016647.g003
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Canary Islands and The Netherlands [50,51,52,53], the largest
being two TB clusters comprising 184 and 272 cases respectively
found over a ten years period in Denmark [54].
In spite of the long transmission time and many carriers of the
cluster SMI-049 strain in the community, the IS6110 RFLP
pattern has stayed virtually unchanged and we found extremely
few genomic changes (4 SNPs and one small deletion) between the
three sequenced isolates that were isolated 9 years apart. This
indicates that the SMI-049 lineage is genetically very stable both
with respect to point mutations and to transpositional activity of
insertion sequences, in contrast with reports of other M. tuberculosis
lineages e.g. the Beijing lineage. Differences in the level of genetic
variability have to be considered in view of the already very low
genetic variability among members of the M. tuberculosis complex.
Our genome sequences are lacking coverage of several PE-PGRS
genes most likely as a result of sequencing bias due to high GC-
content in those genes. It is therefore possible that there exists
more variation between SMI-049 strains than we have detected in
this study.
Niemann et al [18] found that two isolates of the Beijing lineage
from an outbreak in Uzbekistan with identical IS6110 RFLP
fingerprinting pattern exhibited considerable genomic diversity
(130 SNPs and one large deletion). The fact that strains with
identical genotyping patterns can accumulate significant amounts
of genetic diversity indicates that epidemiological links between
strains with identical genotyping data can be more remote and are
likely to represent older transmission events rather than cases of
recent transmission among patients in one RFLP cluster. The two
isolates studied by Niemann et al actually exhibited differences in
MIRU/VNTR as well as in drug resistance patterns, indicating
that they were genetically more remote than indicated by their
identical RFLP pattern. In Estonia genetically closely related
isolates of the Beijing lineage showed a range from full
susceptibility to four-drug resistance, indicating that drug resis-
tance had developed recently and independently in different clones
of Beijing strains [55].
Stability in RFLP
Yeh et al. found that about 30% of serial isolates of patients
whose cultures spanned at least 90 days had changed IS6110
RFLP patterns [56]. In contrast, here we found that the cluster
SMI-049 strain has maintained the same stable IS6110 RFLP
profile over 9 years with only one isolate as an exception. This may
indicate that the SMI-049 strain has a very low transposition
activity of IS6110 despite the presence of 18 copies in the genome.
Low transposition activity is generally thought to occur in genomes
with low number of IS6110 copies (1–5 copies) [57]. However,
transpositional activity has been linked to the transcriptional
activity of the genomic location of IS6110 elements with increased
overall transpositional activity occurring when an IS6110 element
is inserted at a genomic position with strong transcriptional activity
[58]. There also seems to be an upper limit of about 25 IS6110
elements per genome, possibly regulated by a trans acting
repressor expressed from each element that limits the transposi-
tional activity more the more elements are present [24]. If any of
these factors keep the IS6110 pattern of the SMI-049 cluster so
stable is hard to speculate upon.
Stability in drug resistance
Although members of the M. tuberculosis complex have
accumulated a very low general genetic variability since their last
common ancestor, the modern use of anti-TB drugs presents a
new selective pressure that can increase the genetic variability in
genes that render the bacteria drug resistant by selecting those
over their susceptible counterparts. In clinical isolates exposed to
therapy, increased genetic variation should therefore be expected
in drug resistance genes. However, some resistance mutations have
been associated with fitness costs that might result in a reduced
virulence/transmissibility (reviewed in [59]). All initial isolates of
the 115 patients belonging to cluster SMI-049 were resistant to
INH, but susceptible to EB and RIF. In only one instance a strain
developed further resistance: in 2003 a patient was found to be
infected with a strain belonging to the SMI-049 clone and resistant
to INH, in 2004 another isolate with the same fingerprint from the
same patient was in addition resistant to RIF, making the strain
MDR [6]. This mutant variant with increased resistance did not
spread further. It is intriguing that in spite of the long passage of
this strain in the community there has been no further
development of drug resistance. Resistance to INH has been
coupled with various chromosomal mutations but those in katG
and in the promoter regions of inhA have been most frequently
associated with clinical isolates [60,61]. The INH resistance of the
cluster SMI-049 isolates was low level, with a MIC of 0.4 mg/L,
which agrees with the fact that the isolates had the inhA promoter
mutation. Strains with the inhA promoter mutation or the KatG
S315T mutation were more likely to spread than strains with other
mutations, suggesting that these mutations have a low fitness cost
[62] which is in agreement with the stability in INH resistance of
cluster SMI-049.
All three isolates contain the G102 deletion in gidB reported
earlier to give low-level resistance to SM [21,22]. This level of
resistance is just at the clinical resistance break-point and this is
probably why some isolates belonging to the cluster SMI-049 have
been reported as resistant while most isolates are considered
susceptible. We could not find any genomic difference between
isolate S96-129 (SMR) and BTB05-552 (SMS) and BTB05-559
(SMS) that can explain this difference in resistance. Use of SM to
treat infections of SMI-049 should therefore be avoided, especially
since the gidB mutation has been reported to dramatically elevate
the frequency of high-level mutations to SM in M. tuberculosis [22].
On the other hand, SMI-049 isolates are highly sensitive to
quinolones and this group of antibiotics might therefore be useful
for treatment.
Effects of polymorphisms on evolutionary success and
virulence
Large sequence polymorphisms (LSPs) such as deletions and
insertions of IS-elements (mainly IS6110) represent a substantial
source of genetic variation among M. tuberculosis lineages [63,64].
How LSPs in the M. tuberculosis complex may affect the
evolutionary success of certain lineages has been discussed
frequently [64,65,66,67]. There is increasing evidence that certain
M. tuberculosis strains are particularly prone to disseminate and/or
to cause disease [60,68,69,70,71]. There are also several examples
of hypervirulence resulting from gene deletion in M. tuberculosis
[72]. However, the potential pathogenic relevance of most specific
regions of difference is unknown. Interestingly, the Beijing lineage
that is causing concern due to its global distribution and its
involvement in severe outbreaks does not seem to spread in
Sweden [73]. Since the SMI-049 cluster strain has been
extensively spread in Sweden, a country with low incidence of
TB, questions have been raised whether it contains genotypic
determinants that make it particularly prone to disseminate. The
fact that transmission was very high during certain periods [13]
around particular individuals might on the other hand indicate
that part of the extensive transmission may be explained by socio-
demographic factors.
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other M. tuberculosis strains. On the other hand there are several
specific deletions and IS6110 insertions not found elsewhere. The
successful spread of SMI-049 and the fact that it is not attenuated
in growth in human macrophages also shows that deletion of the
genes absent from its genome compared to other sequenced strains
is not likely to be detrimental to virulence. In fact our findings of
the high TNF production in human macrophages infected by
SMI-049 isolates in vitro paralleled by the augmented macrophage
death support the concept of the sustained virulence of SMI-049;
similar induction of increased TNF expression and cellular
necrosis by virulent clinical strains, as compared to H37Rv, have
recently been found in murine macrophages in vitro [74] and in a
mouse model of TB infection [75].
In some instances deletion of genes has been associated with
altered development of M. tuberculosis disease, e.g. Kong et al found
a significant linkage between the deletions of RD105, RD181 and
RD142 (which are markers for Beijing strains) and the occurrence
of extrathoracic tuberculosis [28]. Many of the inactivating
polymorphisms (deletions and IS6110 insertions in genes) specific
for the SMI-049 cluster have occurred in genes belonging to the
PE and PPE-gene families (PE-PGRS44, PPE34, PPE38-39,
PPE57-59). Since these gene classes are thought to play important
roles for the bacterium by generating antigenic variation and
immune evasion, variable occurrence of PE and PPE genes may
change the interaction of the bacterium with its host and thus alter
the progress of the disease.
SMI-049 isolates also have a unique IS6110 inserted at a slightly
different position in the plcD gene (Rv1755) compared to H37Rv.
There are four phospholipase C genes (PLC) in M. tuberculosis,
plcABC as an operon and plcD alone at a separate position in the
genome. All four contribute to PLC activity and are involved in
virulence although their exact role is not fully understood [76].
Expression of the plc-genes is upregulated after infection of
macrophages and the quadruple knock out mutant is attenuated in
growth in lungs and spleen of mice. Interruptions of plc-genes are
frequent among clinical M. tuberculosis isolates and most frequent in
plcD [27,28,77]. It is hypothesized that reduced PLC activity
causes persistence of the bacterium inside macrophages and aid
travel to distant organs. Alternatively, reduced activity limits
release of arachidonic acid from the macrophage membrane and
reduce immune response in the initial lung infection. It is therefore
possible that the clinical presentation of the disease may be
influenced by the genetic variability of the plcD region. It is not
immediately obvious if any of the other genes with annotated
functions affected by inactivating changes would mediate pheno-
typic changes in the cluster SMI-049 strains although dhaA
(encoding a haloalkane dehalogenase) has been shown to be
upregulated upon in vitro infection of a macrophage cell line [78].
In summary, we have found that the cluster SMI-049 strain that
has caused a major outbreak of INH resistant TB in Sweden has
been genetically extremely stable over extended time in the
community and through many transmissions and has not
developed resistance to the antibiotics used to treat patients
infected with the strain. Even though we have found specific
genetic features in this strain not found in other TB strains, the
question why this particular strain of TB has been so successful in
spreading both in the immigrant population where it originated
and also in the Swedish born population remains to be answered.
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